When should you treat your patient early in MF? The rationale behind early intervention of MF is considered and the potential clinical benefits to patients are explained.
“The influence of disease stage on the quality of response, the influence of ruxolitinib dose, early intervention, higher dose, better outcome of the patients.”
Dr Verstovsek highlights the importance of increased knowledge surrounding MF and pre-fibrotic disease. He also helps us to understand the methods for prognostic scoring and dose optimisation in individual patients.